Biotechnology

Liminatus Pharma

Liminatus Pharma released FY2025 Q4 earnings on March 31 (EST) with actual revenue of USD 0 and EPS of USD -0.3014

Liminatus Pharma released FY2025 earnings on March 31 (EST), actual revenue USD 0, actual EPS USD -0.4296

Liminatus Pharma released FY2025 Q3 earnings on November 14, 2025, EST: Actual Revenue USD 0, Actual EPS USD -0.0675

Liminatus Pharma released FY2024 9 Months Earnings on November 14 (EST), actual revenue USD 0, actual EPS USD -0.1895

Liminatus Pharma released FY2024 Q3 earnings on November 14 (EST), actual revenue USD 0, actual EPS USD -0.0343

Liminatus Pharma released FY2025 9 Months earnings on November 14, 2025 (EST), actual revenue USD 0, actual EPS USD -0.0626

Liminatus Pharma released FY2024 Semi-Annual earnings on October 6, 2025 (EST), actual revenue USD 0, actual EPS USD -0.1551

Liminatus Pharma released FY2024 Q2 earnings on October 6 (EST), actual revenue USD 0, actual EPS USD -0.0549

Liminatus Pharma released FY2025 Q2 earnings on October 6 (EST), actual revenue USD 0, actual EPS USD 0.0048

Liminatus Pharma released FY2025 Semi-Annual earnings on October 6 (EST), actual revenue USD 0, actual EPS USD -0.0105

Liminatus Pharma Inc. Enters Cryptocurrency Market Through BNB Investment Strategy

Liminatus Pharma Inc. Issues Common Stock to Alta Partners for Warrant Cancellation

Liminatus Pharma partners with others on pancreatic cancer early detection kit

Liminatus Pharma Inc. Submits Beneficial Ownership Statement

Liminatus Pharma Inc Advances IBA101 Clinical Trials

Liminatus Pharma released FY2025 Q1 earnings on June 2, 2025 (EST) with actual revenue of USD 0 and EPS of USD 0

Liminatus Pharma Delays Filing of First Quarter 2025 Financial Report

Liminatus Pharma released FY2024 Q4 earnings on May 6, 2025 (EST) with actual revenue of USD 0 and EPS of USD -0.0131

Liminatus Pharma released FY2024 Annual Earnings on May 6, 2025 (EST), Actual Revenue: USD 0, Actual EPS: USD -0.2026

Liminatus Pharma released FY2023 Q4 earnings on May 6, 2025 (EST) with actual revenue of USD 0 and EPS of USD -0.0068

Onconetix

Arrive AI

Darkiris - CL

Aimei Health Tech

Generation Income Properties

GameSquare

Yimutian

Galmed Pharma

T-REX 2X Long Eose Daily Target ETF

PMGC

Please note that a "Suspected value trap" is a stock that appears The stock looks financially sound and severely undervalued, but behind the low valuation is a long-term decline in business capacity or a serious financial crisis, or even the risk of bankruptcy in the short term.

Suspected value trap

Liminatus Pharma(LIMN.US)

Liminatus Pharma Stock Performance Chart